Katherine A Lyseng-Williamson

Summary

Affiliation: Adis International Limited
Country: New Zealand

Publications

  1. request reprint
    Perry C, Barman Balfour J, Lamb H. Gatifloxacin. Drugs. 1999;58:683-96; discussion 697-8 pubmed
    ..The drug was reported to be well tolerated. Gatifloxacin does not appear to cause phototoxic effects. ..
  2. request reprint
    Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs. 2000;59:301-21 pubmed
    ..In those with excessive nasal congestion the combination of fexofenadine plus pseudoephedrine may be useful. In clinical trials fexofenadine is not associated with adverse cardiac or cognitive/psychomotor effects. ..
  3. request reprint
    Cvetkovic R, Scott L. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005;65:1005-24 pubmed
    ..01). Dexrazoxane is the only cardioprotective agent with proven efficacy in cancer patients receiving anthracycline chemotherapy and is a valuable option for the prevention of cardiotoxicity in this patient population. ..
  4. request reprint
    Lyseng Williamson K, Simpson D. Budesonide/Formoterol pressurized metered-dose inhaler. Drugs. 2008;68:1855-64 pubmed
    ..Its overall adverse event profile is consistent with the known tolerability profiles of long-acting [beta]2-adrenoceptor agonist and inhaled corticosteroid therapy, and is similar to that shown with placebo. ..
  5. Dhillon S. Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis. Drugs. 2009;69:2005-24 pubmed publisher
    ..Overall, considering the large unmet need for therapeutic options in patients with digital ulcers, bosentan extends the treatment options available to patients with systemic sclerosis-associated digital ulcers. ..
  6. Yang L, Scott L. Palonosetron: in the prevention of nausea and vomiting. Drugs. 2009;69:2257-78 pubmed publisher
    ..Intravenous palonosetron is a useful alternative to currently recommended agents in PONV prevention. ..
  7. request reprint
    Balfour J, Plosker G. Rosiglitazone. Drugs. 1999;57:921-30; discussion 931-2 pubmed
    ..There is no evidence to date that rosiglitazone shares the hepatotoxicity of troglitazone. ..
  8. request reprint
    Hurst M, Spencer C. Ebastine: an update of its use in allergic disorders. Drugs. 2000;59:981-1006 pubmed
    ..Ebastine does not appear to be associated with any significant cardiac adverse events. Ebastine is a useful treatment option for patients with allergic rhinitis or chronic idiopathic urticaria. ..
  9. request reprint
    Frampton J, Easthope S. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol. 2003;4:709-25 pubmed
    ..Repeated injections are necessary to maintain a long-term effect; however, this technique clearly represents an attractive option for individuals who wish to avoid a more major procedure. ..

More Information

Publications201 found, 100 shown here

  1. McCormack P, Joura E. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women. Drugs. 2010;70:2449-74 pubmed publisher
  2. Keating G. Methylphenidate transdermal system: in attention-deficit hyperactivity disorder in adolescents. CNS Drugs. 2011;25:333-42 pubmed publisher
    ..The vast majority of treatment-emergent adverse events were of mild to moderate severity in both the short-term core trial and the longer-term extension study. ..
  3. request reprint
    Oldfield V, Perry C. Spotlight on rasburicase in anticancer therapy-induced hyperuricemia. BioDrugs. 2006;20:197-9 pubmed
    ..Thus, rasburicase is a useful option for the prophylaxis or treatment of anticancer therapy-induced hyperuricemia in both adult and pediatric patients. ..
  4. Moen M. Indacaterol: in chronic obstructive pulmonary disease. Drugs. 2010;70:2269-80 pubmed publisher
    ..Indacaterol was generally well tolerated by adults with moderate to severe COPD. ..
  5. request reprint
    Ormrod D, Holm K, Goa K, Spencer C. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. Drugs Aging. 1999;15:389-416 pubmed
    ..In the meantime there is sufficient evidence to justify consideration of epirubicin for inclusion in first-line therapies for patients with early or metastatic breast cancer. ..
  6. request reprint
    Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs. 2001;61:1325-50 pubmed
    ..Thus mometasone furoate is suitable for the control of mild to severe persistent asthma in adults or adolescents. ..
  7. request reprint
    Cheer S, Waugh J, Noble S. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs. 2003;63:2501-20 pubmed
    ..In the meantime, TSI represents a valuable option for suppressive antipseudomonal therapy in patients with cystic fibrosis. ..
  8. Curran M. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Paediatr Drugs. 2012;14:51-60 pubmed publisher
    ..Everolimus was generally well tolerated in patients with SEGA associated with TSC; most drug-related adverse reactions were mild to moderate in severity. ..
  9. Duggan S, Scott L. Intravenous paracetamol (acetaminophen). Drugs. 2009;69:101-13 pubmed publisher
    ..Additionally, adverse reactions emerging from the use of the intravenous formulation of paracetamol are extremely rare (<1/10 000). [table: see text]. ..
  10. Dhillon S. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa). BioDrugs. 2010;24:299-302 pubmed publisher
  11. McKeage K, Deeks E. Doxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol. 2010;11:217-22 pubmed publisher
    ..Anti-inflammatory dose doxycycline 40 mg was generally well tolerated in clinical trials, with most adverse events being of mild to moderate intensity. ..
  12. request reprint
    Curran M, Perry C. Spotlight on amisulpride in schizophrenia. CNS Drugs. 2002;16:207-11 pubmed
    ..Amisulpride is a first-line treatment option in the management of schizophrenia in the acute phase and for the maintenance of treatment response. ..
  13. request reprint
    Hair P, Scott L. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs. 2006;66:973-96 pubmed
    ..Overall, levocetirizine is a valuable addition to the oral H(1) receptor antagonists available for the treatment of allergic rhinitis and as first-line therapy in patients with CIU. ..
  14. Deeks E. Icatibant. Drugs. 2010;70:73-81 pubmed publisher
  15. request reprint
    McNeely W, Goa K. 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs. 1998;56:667-90 pubmed
    ..Nevertheless, in appropriately selected patients, PUVA 5-methoxypsoralen therapy may be recommended as an alternative first-line systemic treatment option for the management of vitiligo or psoriasis. ..
  16. Carter N, Curran M. Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs. 2011;71:1591-622 pubmed publisher
    ..In the US, LAIV is indicated for the active immunization of healthy subjects aged 2-49 years against influenza disease caused by virus subtypes A and type B contained in the vaccine. ..
  17. request reprint
    McClellan K, Plosker G. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. Drugs. 1999;58:143-57 pubmed
    ..The role of trimetazidine in other coronary conditions has yet to be clearly established. ..
  18. request reprint
    McCormack P, Keam S. Rotavirus vaccine RIX4414 (Rotarix): a review of its use in the prevention of rotavirus gastroenteritis. Paediatr Drugs. 2009;11:75-88 pubmed
    ..Therefore, rotavirus vaccine RIX4414 offers a highly effective control strategy for reducing the burden of RVGE in infants. ..
  19. Plosker G, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs Aging. 2009;26:893-915 pubmed publisher
  20. Hoy S, Keating G. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 2011;71:1481-501 pubmed publisher
  21. request reprint
    Balfour J, Goa K. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 1997;54:273-98 pubmed
    ..Further studies are required to determine whether it offers any advantages over other agents in these settings and to determine the optimum dosage for preventing RINV. ..
  22. Duggan S, Plosker G. Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]. Drugs. 2009;69:115-22 pubmed publisher
    ..fig: see text] ..
  23. Carter N, Keam S. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs. 2010;70:355-76 pubmed publisher
  24. Curran M, Leroux Roels I. Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly. Drugs. 2010;70:1519-43 pubmed publisher
    ..In conclusion, Fluarix is an important means of decreasing the impact of seasonal influenza viruses on adults and the elderly. ..
  25. Dhillon S. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs. 2011;71:1209-31 pubmed publisher
  26. Plosker G. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries. Pharmacoeconomics. 2011;29:989-1009 pubmed publisher
  27. Duggan S. Fidaxomicin: in Clostridium difficile infection. Drugs. 2011;71:2445-56 pubmed publisher
    ..Fidaxomicin was generally well tolerated in patients with C. difficile infection, with a tolerability profile generally similar to that of vancomycin. ..
  28. request reprint
    Hvizdos K, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs. 2000;60:1141-78 pubmed
    ..The preparation is suitable for use in infants, children and adults with persistent asthma and in infants and children with croup. ..
  29. request reprint
    Wagstaff A, Frampton J, Croom K. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs. 2003;63:1101-20 pubmed
  30. request reprint
    Siddiqui M, Plosker G. Rasagiline. Drugs Aging. 2005;22:83-91; discussion 93-4 pubmed
    ..Adverse events with rasagiline were generally similar in frequency to those seen in placebo or entacapone recipients. ..
  31. request reprint
    Keating G, Scott L. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone. Drugs. 2007;67:793-804 pubmed
    ..Preliminary results suggest that zoledronic acid is a cost-effective option in Paget's disease of bone. Thus, zoledronic acid is an important first-line treatment for Paget's disease of bone. ..
  32. Frampton J, Perry C. Ibandronate: a review of its use in the management of postmenopausal osteoporosis. Drugs. 2008;68:2683-707 pubmed publisher
    ..Thus, intermittent ibandronate extends the range of pharmacological therapies for the treatment and prevention of postmenopausal osteoporosis. ..
  33. request reprint
    Scott L, Spencer C. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000;59:521-49 pubmed
    ..Miglitol may prove particularly beneficial in elderly patients and those with hepatic impairment or mild to moderate renal impairment, in whom other oral antidiabetic agents are contraindicated or need to be used with caution. ..
  34. request reprint
    Perry C, Ibbotson T. Biapenem. Drugs. 2002;62:2221-34; discussion 2235 pubmed
    ..Biapenem is generally well tolerated. The most common adverse events in clinical trials were skin eruptions/rashes, nausea and diarrhoea. ..
  35. Frampton J, Lyseng Williamson K. Degarelix. Drugs. 2009;69:1967-76 pubmed publisher
    ..Degarelix treatment for 1 year was generally well tolerated; the adverse events reported were mostly related to subcutaneous drug administration (i.e. injection-site reactions) and hormonal androgen deprivation (e.g. hot flushes). ..
  36. Hoy S, Scott L, Keating G. Intramuscular paliperidone palmitate. CNS Drugs. 2010;24:227-44 pubmed publisher
    ..Intramuscular paliperidone palmitate 39-234 mg was generally well tolerated in adult patients with schizophrenia. ..
  37. Croxtall J, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs. 2010;70:2259-67 pubmed publisher
    ..In general, combination therapy with trastuzumab and chemotherapy was relatively well tolerated in patients with metastatic gastric cancer with no reports of new or unexpected adverse events. ..
  38. request reprint
    Hurst M, Lamb H. Meropenem: a review of its use in patients in intensive care. Drugs. 2000;59:653-80 pubmed
    ..Meropenem has an important role in the empirical treatment of serious infections in adults and children in ICUs. ..
  39. request reprint
    Curran M, Perry C. Amisulpride: a review of its use in the management of schizophrenia. Drugs. 2001;61:2123-50 pubmed
    ..Amisulpride is a first-line treatment option in the management of schizophrenia in the acute phase and for the maintenance of treatment response. ..
  40. request reprint
    McCormack P, Wagstaff A. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs. 2006;66:931-8 pubmed
    ..The allergy vaccine was generally well tolerated. Local reactions, mainly injection-site redness and swelling, were more common than systemic reactions. There were no serious adverse events. ..
  41. McKeage K, Keam S. Pregabalin: in the treatment of postherpetic neuralgia. Drugs Aging. 2009;26:883-92 pubmed publisher
    ..Pregabalin was generally well tolerated when titrated over 1 week to fixed dosages (maximum 600 mg/day) in clinical trials in mostly elderly PHN patients. Adverse events were usually mild to moderate in severity. ..
  42. Lyseng Williamson K. Oral bepotastine: in allergic disorders. Drugs. 2010;70:1579-91 pubmed publisher
    ..Bepotastine was generally well tolerated in adult and paediatric patients with allergic conditions. ..
  43. request reprint
    Perry C, Markham A. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs. 1999;57:805-43 pubmed
  44. request reprint
    Keating G, Scott L. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs. 2004;64:2347-77 pubmed
    ..Thus, moxifloxacin is an important option in the treatment of bacterial infections. ..
  45. Hoy S, McKeage K. Temsirolimus: In relapsed and/or refractory mantle cell lymphoma. Drugs. 2010;70:1819-29 pubmed publisher
    ..Adverse events were often managed with dose modifications. ..
  46. request reprint
    Wilde M, Wagstaff A. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs. 1997;53:1038-53 pubmed
    ..Longer term and comparative trials with other active therapies are required to confirm these promising results. ..
  47. request reprint
    Coukell A, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging. 1998;12:149-68 pubmed
    ..It is an effective treatment for Paget's disease and is the treatment of choice where oral bisphosphonates are not an option. ..
  48. request reprint
    McClellan K, Jarvis B. Desloratadine. Drugs. 2001;61:789-96; discussion 797 pubmed
    ..Sleep and daytime performance also improved. Desloratadine was well tolerated in clinical trials and had an adverse event profile similar to that of placebo in patients with SAR (with or without asthma) or CIU. ..
  49. request reprint
    Dando T, Wiseman L. Clodronate : a review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer. Drugs Aging. 2004;21:949-62 pubmed
    ..In the meantime, clodronate is a well established bisphosphonate which has shown beneficial effects in the prevention of bone metastases and on survival in patients with primary breast cancer. ..
  50. request reprint
    Anderson V, Curran M. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs. 2007;67:1947-67 pubmed
    ..parvum or G. lamblia infection in immunocompetent adults and children, and is an option to be considered in the treatment of illnesses caused by other protozoa and/or helminths. ..
  51. Dhillon S, Weber J. Saxagliptin. Drugs. 2009;69:2103-14 pubmed publisher
    ..Saxagliptin therapy was not associated with an increased risk of cardiovascular events according to pooled data from eight clinical trials. Saxagliptin generally had a weight-neutral effect. ..
  52. Frampton J. Prucalopride. Drugs. 2009;69:2463-76 pubmed publisher
    ..Moreover, prucalopride at dosages up to 20 mg/day (10-fold higher than the recommended therapeutic dosage) had no clinically relevant effects on cardiovascular parameters in healthy volunteers. ..
  53. Dhillon S. Tramadol/paracetamol fixed-dose combination: a review of its use in the management of moderate to severe pain. Clin Drug Investig. 2010;30:711-38 pubmed publisher
  54. Scott L. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults. BioDrugs. 2010;24:387-406 pubmed publisher
  55. Deeks E, Perry C. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs. 2010;70:2315-38 pubmed publisher
  56. Deeks E. Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension. Drugs. 2011;71:209-20 pubmed publisher
    ..Olmesartan medoxomil?+?amlodipine?+?HCTZ was generally well tolerated in the TRINITY study, with adverse events usually being mild or moderate in severity. ..
  57. Lyseng Williamson K, Yang L. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma. Am J Clin Dermatol. 2012;13:67-71 pubmed publisher
    ..Romidepsin had an acceptable tolerability profile, with the most common grade 3 or 4 adverse events considered at least possibly related to romidepsin being hematologic or asthenic in nature. ..
  58. request reprint
    Lamb H, Figgitt D, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999;58:1061-97 pubmed
    ..However, in VREF or unresponsive MRSA infections, where few proven treatment options exist, quinupristin/dalfopristin should be considered as a treatment of choice for these seriously ill patients. ..
  59. request reprint
    Dunn C, Goa K. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs. 2001;61:685-712 pubmed
    ..The effects of the drug on hip fracture incidence in elderly women with confirmed osteoporosis point to a particular role in older patients, or those with more advanced disease. ..
  60. request reprint
    Jarvis B, Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging. 2001;18:441-72 pubmed
    ..These qualities make the drug suitable for first-line use in patients with COPD who require regular bronchodilator therapy to manage symptoms. ..
  61. request reprint
    Matheson A, Cheer S, Goa K. Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension. Drugs. 2001;61:1211-29 pubmed
    ..The fixed-low dose combination of perindopril/indapamide provides a promising and well tolerated treatment option in the management of patients with mild to moderate hypertension. ..
  62. Carter N, Scott L. Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70:83-97 pubmed publisher
    ..6% was generally well tolerated in clinical trials, with most adverse events being mild in severity. The tolerability profile of besifloxacin ophthalmic suspension 0.6% was similar to that of moxifloxacin ophthalmic solution 0.5%. ..
  63. Garnock Jones K, Scott L. Fospropofol. Drugs. 2010;70:469-77 pubmed publisher
    ..Patients undergoing flexible bronchoscopy appeared to have a higher rate of sedation-related adverse events requiring airway assistance than did those undergoing colonoscopy or minor procedures. ..
  64. Dhillon S. DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination. Drugs. 2010;70:1021-58 pubmed publisher
  65. McCormack P, Joura E. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women. BioDrugs. 2011;25:339-43 pubmed publisher
  66. request reprint
    Ormrod D, McClellan K. Topiramate: a review of its use in childhood epilepsy. Paediatr Drugs. 2001;3:293-319 pubmed
    ..Although comparative studies with the other newer AEDs used in adjuntive therapy are required, topiramate is an important extension to the range of drugs that may be used to treat refractory epilepsy in children. ..
  67. McCormack P, Robinson D. Eslicarbazepine acetate. CNS Drugs. 2009;23:71-9 pubmed publisher
    ..Eslicarbazepine acetate was generally well tolerated in clinical trials. The majority of treatment-emergent adverse events were of mild to moderate severity and most occurred early in treatment. ..
  68. Garnock Jones K, Keating G. Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia. Drugs. 2009;69:2149-65 pubmed publisher
    ..Thus, the lidocaine 5% medicated plaster is a useful first-line option for the treatment of patients with PHN. ..
  69. Plosker G. Aztreonam lysine for inhalation solution: in cystic fibrosis. Drugs. 2010;70:1843-55 pubmed publisher
    ..aeruginosa density in sputum in clinical trials. The tolerability profile of AZLI was generally similar to that of placebo in randomized controlled trials, with respiratory symptoms being the most frequently reported adverse events. ..
  70. Garnock Jones K. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2011;11:57-72 pubmed publisher
    ..Dabigatran etexilate is a promising new option for the prevention of stroke and systemic embolism in patients with atrial fibrillation. ..
  71. Duggan S, Scott L. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation. Drugs. 2011;71:237-52 pubmed publisher
    ..Therefore, intravenous vernakalant provides an effective option for the management of recent-onset atrial fibrillation. ..
  72. Chwieduk C, Scott L. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder. CNS Drugs. 2011;25:251-67 pubmed publisher
    ..In the meantime, asenapine is a further option for the management of manic and/or mixed symptoms in patients with bipolar I disorder and may be of particular value for patients who are at high risk for metabolic abnormalities. ..
  73. request reprint
    Keam S, Scott L. Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68:463-85 pubmed
  74. Frampton J, Moen M. Vinflunine. Drugs. 2010;70:1283-93 pubmed publisher
    ..g. neutropenia) and gastrointestinal symptoms (e.g. constipation). In general, adverse events with vinflunine were noncumulative and medically manageable. ..
  75. Keating G. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. 2011;71:1623-47 pubmed publisher
    ..In conclusion, plerixafor is a valuable stem-cell mobilizer for use in combination with G-CSF in patients with lymphoma or MM, particularly in patients who are poor mobilizers or predicted poor mobilizers. ..
  76. request reprint
    Plosker G, Noble S. Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs. 1999;58:325-45 pubmed
    ..Although the extent of its use may be limited by its adverse event profile, cidofovir offers a useful addition to the limited number of drugs available for the treatment of CMV retinitis in patients with AIDS. ..
  77. request reprint
    Foster R, Plosker G. Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. Pharmacoeconomics. 2000;18:289-306 pubmed
    ..There are limitations to the present data, but the available pharmacoeconomic data have been favourable for glipizide GITS. ..
  78. request reprint
    Fulton B, Perry C. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. Paediatr Drugs. 2001;3:137-58 pubmed
    ..Based on these characteristics, cefpodoxime proxetil is a suitable option for the treatment of paediatric patients with various common bacterial infections. ..
  79. request reprint
    Lyseng Williamson K, Plosker G. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics. 2007;25:1007-29 pubmed
  80. Wagstaff A. Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma. Drugs. 2009;69:319-26 pubmed publisher
    ..Plerixafor appears to be generally well tolerated; most adverse effects in clinical trials were mild and transient. ..
  81. Croxtall J, Keating G. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs. 2009;11:349-57 pubmed publisher
    ..6% in 11Pn-PD vaccinees compared with recipients of a control vaccine (primary endpoint). The tolerability profile of PHiD-CV was generally similar to that of 7vCRM. ..
  82. Frampton J. Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs. 2010;12:141-53 pubmed publisher
    ..Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma. ..
  83. McKeage K, Keam S. Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs. 2010;70:1857-83 pubmed publisher
    ..Thus, telbivudine provides a valuable treatment option in CHB, particularly when administered using the Roadmap concept in HbeAg-positive patients. ..
  84. Lyseng Williamson K. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. Pharmacoeconomics. 2011;29:251-68 pubmed publisher
  85. Dhillon S. Naproxen/esomeprazole fixed-dose combination: for the treatment of arthritic symptoms and to reduce the risk of gastric ulcers. Drugs Aging. 2011;28:237-48 pubmed publisher
    ..The fixed-dose combination was generally well tolerated in these studies, with an upper gastrointestinal tolerability profile generally better than that of naproxen and similar to that of celecoxib. ..
  86. request reprint
    Wilde M, Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs. 1997;54:903-24 pubmed
    ..The drug has low cross-reactivity with HIT-associated antibodies. Further comparative trials are needed to confirm these promising findings. ..
  87. request reprint
    Keating G, Perry C. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs. 2002;16:111-48 pubmed
  88. request reprint
    Bang L, Easthope S, Perry C. Transdermal oxybutynin: for overactive bladder. Drugs Aging. 2003;20:857-64 pubmed
    ..Adverse events associated with anticholinergic drugs (e.g. dry mouth) were less frequently reported in patients treated with transdermal oxybutynin than in those receiving orally administered oxybutynin or tolterodine. ..
  89. request reprint
    Scott L, Figgitt D, Keam S, Waugh J. Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence. CNS Drugs. 2005;19:445-64 pubmed
    ..Thus, in combination with psychosocial and behavioural management programmes, acamprosate is a promising option for the maintenance of abstinence in alcohol-dependent patients after alcohol withdrawal. ..
  90. request reprint
    Goldsmith D, Wellington K. Naftidrofuryl: a review of its use in the treatment of intermittent claudication. Drugs Aging. 2005;22:967-77 pubmed
    ..The magnitude of these effects appears to support claims that the effects of naftidrofuryl are clinically relevant in these patients. ..
  91. request reprint
    Moen M, Scott L. Recombinant full-length parathyroid hormone (1-84). Drugs. 2006;66:2371-81; discussion 2382-5 pubmed
    ..PTH(1-84) is generally well tolerated, although patients should be monitored for elevated serum calcium. ..
  92. McKeage K, Keating G. Tigecycline: in community-acquired pneumonia. Drugs. 2008;68:2633-44 pubmed publisher
    ..Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population. Tigecycline was generally well tolerated in patients with CAP. ..